Abstract 19032: GLP-1 Receptor Agonists Added to Statin Therapy and Cardiovascular Outcomes in Patients with Atherosclerotic Cardiovascular Disease and Obesity
Abstract
Background: Statins reduce cardiovascular events in atherosclerotic cardiovascular disease (ASCVD), yet residual risk remains high in patients with obesity. Whether adding a GLP-1 receptor agonist (GLP-1 RA) to statin therapy further reduces mortality, myocardial infarction (MI), and ischemic stroke in this population is unknown. Methods: This retrospective propensity score-matched cohort study used the TriNetX Research Network (108 U.S. healthcare organizations; data through November 2025). Adults with ASCVD and body mass index ≥30 kg/m 2 on statin therapy who initiated a GLP-1 RA (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) were compared to statin-only controls. Patients with type 1 diabetes, prior bariatric surgery, or pregnancy were excluded. Co-primary outcomes were all-cause mortality, MI, and ischemic stroke over 3 years. Matching on 34 covariates yielded 119,911 pairs (all standardized mean differences <0.10). Cox proportional hazards regression yielded hazard ratios (HRs) with 95% confidence intervals (CIs). Prespecified sensitivity analyses included four washout windows (30-120 days) and a familial hypercholesterolemia (FH) exclusion analysis removing patients with baseline LDL ≥190 mg/dL (161,312 matched pairs). Results: Before matching, 166,278 GLP-1 RA users and 920,176 statin-only patients were identified. The matched cohort (N=239,822) had mean age 63 years, 44% female, and 74% White race. GLP-1 RA use was associated with lower all-cause mortality (4.0% vs. 7.5%; HR 0.479; 95% CI: 0.463-0.496), MI (6.0% vs. 7.1%; HR 0.762; 95% CI: 0.737-0.788), and ischemic stroke (0.3% vs. 0.4%; HR 0.671; 95% CI: 0.588-0.766; all p<0.001). GLP-1 RA users were more likely to achieve LDL <55 mg/dL (17.1% vs. 15.3%; RR 1.118; 95% CI: 1.096-1.141; p<0.001). The FH exclusion analysis preserved and strengthened the mortality benefit (HR 0.348; 95% CI: 0.337-0.360; p<0.001). Findings were consistent across all washout sensitivity analyses. Conclusions: In obese ASCVD patients on statins, adding a GLP-1 RA was associated with a 52% relative mortality reduction, 24% lower MI risk, and 34% lower stroke risk — benefits robust to FH exclusion and multiple sensitivity analyses. These findings support prospective randomized evaluation of GLP-1 RAs as cardioprotective adjuncts to statin therapy.